Updates in Relapsed/Refractory Myeloma

Video

Important considerations regarding the sequencing of IMid–versus–PI-based approaches for relapsed/refractory multiple myeloma based on updates presented at the ASH 2020 Virtual Meeting.

Data from the following presentations are discussed:

  • Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 CANDOR study. (Dimopoulos, ASH 2020 Abstract 2325)
    • Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 CANDOR Study in Patients With Early or Late Relapse. (Weisel, ASH 2020 Abstract 2287)

    • Evaluation of Minimal Residual Disease (MRD) Negativity in Patients With Relapsed or Refractory Multiple Myeloma Treated in the CANDOR Study. (Landgren, ASH 2020 Abstract 2282)

  • Isatuxumab Plus Carfilzomib and Dexamethasone vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-label Study. (Moreau, ASH 2020 Abstract 2316)

  • APOLLO: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). (Dimopoulos, ASH 2020 Abstract 412)

  • A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. (Sebag, ASH 2020, Abstract 413)

Related Videos
Ariel F. Grajales-Cruz, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
James K. McCloskey, MD, an expert on leukemia
James K. McCloskey, MD, an expert on leukemia
A panel of 4 experts on MDS
A panel of 4 experts on MDS
Joshua Richter, MD